This Phase 3 trial tests whether adding an experimental immunotherapy called PDS0101 to the standard drug pembrolizumab helps people with advanced HPV16-positive head and neck cancer live longer. About 252 participants will receive either the combination or pembrolizumab alone. T…
Phase: PHASE3 • Sponsor: PDS Biotechnology Corp. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC